These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1005 related articles for article (PubMed ID: 33933106)

  • 21. Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases.
    Lee EJ; Lim YM; Kim S; Choi L; Kim H; Kim K; Kim HW; Lee JS; Kim KK
    Ann Clin Transl Neurol; 2020 Jun; 7(6):992-1001. PubMed ID: 32495489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
    J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differentiated pattern of complement system activation between MOG-IgG-associated disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder.
    Cho EB; Min JH; Waters P; Jeon M; Ju ES; Kim HJ; Kim SH; Shin HY; Kang SY; Lim YM; Oh SY; Lee HL; Sohn E; Lee SS; Oh J; Kim S; Huh SY; Cho JY; Seok JM; Kim BJ; Kim BJ
    Front Immunol; 2024; 15():1320094. PubMed ID: 38576611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
    Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
    JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis.
    Meier S; Willemse EAJ; Schaedelin S; Oechtering J; Lorscheider J; Melie-Garcia L; Cagol A; Barakovic M; Galbusera R; Subramaniam S; Barro C; Abdelhak A; Thebault S; Achtnichts L; Lalive P; Müller S; Pot C; Salmen A; Disanto G; Zecca C; D'Souza M; Orleth A; Khalil M; Buchmann A; Du Pasquier R; Yaldizli Ö; Derfuss T; Berger K; Hermesdorf M; Wiendl H; Piehl F; Battaglini M; Fischer U; Kappos L; Gobbi C; Granziera C; Bridel C; Leppert D; Maleska Maceski A; Benkert P; Kuhle J
    JAMA Neurol; 2023 Mar; 80(3):287-297. PubMed ID: 36745446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
    Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
    Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CSF GFAP levels in double seronegative neuromyelitis optica spectrum disorder: no evidence of astrocyte damage.
    Hyun JW; Kim Y; Kim KH; Kim SH; Olesen MN; Asgari N; Siritho S; Paul F; Kim HJ
    J Neuroinflammation; 2022 Apr; 19(1):86. PubMed ID: 35413922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the complement system in neuromyelitis optica spectrum disorder.
    Asavapanumas N; Tradtrantip L; Verkman AS
    Expert Opin Biol Ther; 2021 Aug; 21(8):1073-1086. PubMed ID: 33513036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis.
    Fan S; Xu Y; Ren H; Guan H; Feng F; Gao X; Ding D; Fang F; Shan G; Guan T; Zhang Y; Dai Y; Yao M; Peng B; Zhu Y; Cui L
    Mult Scler Relat Disord; 2018 Feb; 20():144-152. PubMed ID: 29414288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis.
    Barro C; Healy BC; Liu Y; Saxena S; Paul A; Polgar-Turcsanyi M; Guttmann CRG; Bakshi R; Kropshofer H; Weiner HL; Chitnis T
    Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36376097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes.
    Bose G; Healy BC; Saxena S; Saleh F; Paul A; Barro C; Lokhande HA; Polgar-Turcsanyi M; Anderson M; Glanz BI; Guttmann CRG; Bakshi R; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2023 Jun; 74():104695. PubMed ID: 37060852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical features of MOGAD with brainstem involvement in the initial attack versus NMOSD and MS.
    Xu Q; Yang X; Qiu Z; Li D; Wang H; Ye H; Jiao L; Zhang J; Di L; Lei P; Dong H; Liu Z
    Mult Scler Relat Disord; 2023 Sep; 77():104797. PubMed ID: 37402345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder.
    Min W; Zhang L; Wang S; Xue M; Guo C; Zhu M
    Mult Scler Relat Disord; 2023 Feb; 70():104517. PubMed ID: 36708681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of clinical and radiological characteristics in autoimmune GFAP astrocytopathy, MOGAD and AQP4-IgG
    Xiao J; Zhang SQ; Chen X; Tang Y; Chen M; Shang K; Deng G; Qin C; Tian DS
    Mult Scler Relat Disord; 2022 Oct; 66():104057. PubMed ID: 35870369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosis.
    Molazadeh N; Akaishi T; Bose G; Nishiyama S; Chitnis T; Levy M
    Mult Scler Relat Disord; 2023 Dec; 80():105093. PubMed ID: 37949025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical value of the albumin quotient in patients with neuromyelitis optica spectrum disorder.
    Chen B; Qin C; Tao R; Dong YJ; Ma X; Chen M; Wu LJ; Bu BT; Tian DS
    Mult Scler Relat Disord; 2020 Feb; 38():101880. PubMed ID: 31812873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of clinical characteristics and prognoses in patients with different AQP4-Ab and MOG-Ab serostatus with neuromyelitis optica spectrum disorders.
    Du Q; Shi Z; Chen H; Zhang Y; Wang J; Qiu Y; Zhao Z; Zhang Q; Zhou H
    J Neuroimmunol; 2021 Apr; 353():577494. PubMed ID: 33515897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application of the 2015 neuromyelitis optica spectrum disorders diagnostic criteria in a cohort of Chinese patients.
    He M; Wu L; Huang D; Yu S
    Mult Scler Relat Disord; 2020 Nov; 46():102459. PubMed ID: 32853894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Late onset neuromyelitis optica spectrum disorder with anti-aquaporin 4 and anti-myelin oligodendrocyte glycoprotein antibodies.
    Wang L; Tan H; Huang W; Chang X; ZhangBao J; Zhou L; Lu C; Wang M; Lu J; Zhao C; Quan C
    Eur J Neurol; 2022 Apr; 29(4):1128-1135. PubMed ID: 34967093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical analysis of neuromyelitis optica spectrum disorders in childhood].
    Zhou J; Zhang Y; Ji TY; Jin YW; Bao XH; Zhang YH; Xiong H; Chang XZ; Jiang YW; Wu Y
    Zhonghua Er Ke Za Zhi; 2019 Feb; 57(2):118-124. PubMed ID: 30695886
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.